Pramipexole

證據等級: L5

預測適應症: 10 個

Pramipexole: From Parkinson’s Disease/Restless Legs Syndrome to Attention-Deficit/Hyperactivity Disorder (ADHD)

One-Sentence Summary

Pramipexole is an internationally established non-ergot dopamine D2/D3 receptor agonist, historically used for Parkinson’s disease and restless legs syndrome. The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), but this direction is currently supported by only 1 loosely-related clinical trial and 9 publications, none of which are a direct ADHD efficacy trial.

Quick Overview

Item	Content
Original Indication	Not available from ARTG/TGA data (drug not currently marketed in Australia); internationally used for Parkinson’s disease and restless legs syndrome
Predicted New Indication	Attention-Deficit/Hyperactivity Disorder (ADHD)
TxGNN Prediction Score	99.99%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

A fully documented mechanism-of-action record is not available for pramipexole in this evidence pack (data gap). Elsewhere in the collected evidence, pramipexole is described as a non-ergot dopamine agonist with high selectivity for the D3 receptor subtype (D3 > D2), acting as a full post-synaptic agonist — distinct from ergot-derived dopamine agonists. Its efficacy in Parkinson’s disease and restless legs syndrome, both linked to central dopaminergic deficits, is internationally well established, though no formal Australian regulatory or MOA record exists in this pack.

ADHD is hypothesised to involve prefrontal-cortical dopaminergic hypofunction, so in theory a dopamine agonist could improve attentional regulation — this is the mechanistic thread TxGNN is likely picking up on. However, the drug’s own repurposing rationale flags an important caveat: standard ADHD pharmacotherapy (e.g. methylphenidate, atomoxetine) works by inhibiting dopamine/noradrenaline reuptake to raise synaptic concentrations, whereas pramipexole is a direct post-synaptic receptor agonist — a different, and not necessarily complementary, mechanism.

Consistent with this, the supporting evidence is indirect rather than disease-specific: it largely comes from populations with ADHD as a comorbidity alongside restless legs syndrome or Tourette’s syndrome, from a single case report, and from basic receptor pharmacology studies — not from a trial enrolling primary ADHD patients to test pramipexole as a treatment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00558766	N/A	Completed	35	Studied motor cortex reward signalling (via TMS) in Parkinson’s disease patients on dopaminergic therapy; population is PD, not ADHD — relevance graded C (low), reflects shared dopamine-reward mechanism only, not a direct ADHD trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22407510	2012	RCT	Movement Disorders	Multicenter placebo-controlled RCT of pramipexole for Tourette’s syndrome (dopamine hypersensitivity hypothesis), not ADHD itself
24992083	2014	RCT (different drug)	Clinical Neuropharmacology	11-week RCT comparing piribedil vs pramipexole/ropinirole on vigilance in Parkinson’s disease with daytime sleepiness
18656214	2008	Review	Revue Neurologique	Review of restless legs syndrome pathophysiology and dopaminergic treatment
19412489	2006	Review	Neuropsychiatric Disease and Treatment	Reviews pramipexole’s repurposing for restless legs syndrome, an ADHD-comorbid condition
15540638	2004	Cohort	Developmental Medicine & Child Neurology	Cohort of prepubertal children with sleep disturbance/periodic leg movements; some treated with pramipexole, ADHD noted as a comorbid association
37342213	2023	Case Report	Frontiers in Pain Research	Single case of chronic low back pain/oral dysesthesia with comorbid ADHD, remission with combined atomoxetine and pramipexole
38649244	2024	Case Report (unrelated)	BMJ Case Reports	Case of hypokalaemia from excessive cola consumption; patient incidentally had ADHD and was on pramipexole — not evidence of efficacy
24079375	2013	Animal Study	Journal of Motor Behavior	Spontaneously hypertensive rat model proposed for RLS/PLM, with clinical note that RLS/PLM and ADHD may co-occur
34182128	2021	Basic/Receptor Pharmacology	Pharmacological Research	In vitro receptor heteromerization study (α2A-adrenoceptor/D4 receptor) relevant to ADHD pharmacology in general, not pramipexole-specific efficacy

Australia Market Information

Pramipexole is not currently registered on the ARTG and has no marketed products in Australia in this evidence pack (0 licences on file). No TGA-approved Product Information is therefore available locally.

Safety Considerations

No Australian TGA-approved Product Information is available for this drug (not marketed), and no key warnings, contraindications, or drug-interaction data were retrievable from the sources queried for this evidence pack. Prescribers should consult the manufacturer’s international product information (e.g. from a jurisdiction where pramipexole is registered) for safety data until local TFDA/TGA-equivalent documentation is obtained.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for pramipexole in ADHD is at the mechanism/preclinical level (L4) — the single clinical trial identified enrolled Parkinson’s disease patients, not ADHD patients, and the literature is dominated by comorbid-condition case reports, animal studies, and receptor pharmacology rather than a trial testing pramipexole as an ADHD treatment. The proposed mechanism (direct post-synaptic dopamine agonism) also diverges from standard ADHD pharmacology (reuptake inhibition), which further weakens the case for proceeding.

To proceed, the following is needed:

A clinical trial or controlled study testing pramipexole specifically in primary ADHD (not comorbid RLS/Tourette’s populations)
Resolution of the two blocking/high-severity data gaps: TFDA/TGA-equivalent product warnings and contraindications (DG001, blocking), and a verified mechanism-of-action record (DG002)
Confirmation of an ARTG registration or import pathway, since the drug is currently unmarketed in Australia

Separately worth noting: among the other candidates in this evidence pack, pramipexole as adjunct therapy for schizophrenia (negative symptoms) shows substantially stronger evidence — Evidence Level L2, multiple RCTs, and a systematic review/meta-analysis, with a recommendation of “Research Question with Guardrails.” That candidate may warrant its own dedicated evaluation report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.